HR-positive/HER2-negative breast cancer grows with estrogen or progesterone, lacking high HER2 protein levels, making hormone-blocking treatments crucial. Diagnosis ...

New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.

Discover how advancements in HER2-positive breast cancer treatment enhance patient outcomes through personalized therapies and innovative strategies for both early and metastatic stages. Over the past ...

The metastatic HER2-positive breast cancer market outlook continues to be promising, supported by ongoing innovation, expanding therapeutic indications, lifecycle management initiatives, and ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This ...

Researchers are investigating whether blood tests and heart scans can detect hidden heart damage during breast cancer ...

Triple-positive breast cancer involves tumors positive for estrogen, progesterone, and HER2 receptors, affecting treatment decisions and strategies. Diagnosis includes imaging and biopsy to confirm ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents-antibody-drug conjugates (ADCs)-can dramatically improve ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Lajos Pusztai, MD, ...

If you have metastatic breast cancer that’s hormone receptor-positive (HR+) and HER2-negative, your treatment plan looks very different from how it might have decades ago. Instead of relying on ...

The approval covers the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult patients.